Table 1.
Institution | Year | Tumor Type | Medicine and Administration | Clinical Outcome | Ref. |
---|---|---|---|---|---|
Osaka University, Japan |
2001–2009 | HNC 26 | BSH, 0 or 5 g/body in 1 h (12 h before BNCT) BPA, 250 or 500 mg/kg in 1 h (1 h before BNCT) (Some patients received 2–3 BNCT sessions) |
MST: 13.6 M (post-BNCT) 6-year OS: 24% |
[56] |
Kyoto University, Japan |
2001–2007 | HNC 62 | BSH, 0 or 5 g/body in 1 h (12 h before BNCT) BPA, 250 or 500 mg/kg in 2–3 h (2 h before BNCT) |
MST: 10.1 M (post-BNCT) 1-year OS: 42% 2-year OS: 24% |
[57] |
2012 | r Lung Cancer 01 |
BPA, 400 mg/kg in 2 h (2 h before BNCT) BPA, 100 mg/kg in 1 h (during BNCT) (After one month, they received the second BNCT session) |
PFS: 7 M | [58] | |
JRR-4, University of Tsukuba, Japan |
1999–2002 | nGBM 05 | BSH, 100 mg/kg in 1~1.5 h (IO-BNCT) |
MST: 23.2 M (post-BNCT) | [59] |
1999–2002 | AA 04 | BSH, 100 mg/kg in 1~1.5 h (IO-BNCT) |
MST: 25.9 M (post-BNCT) | [59] | |
1998–2007 | nGBM 07 | BSH, 5 g/body in 1 h (IO-BNCT) |
MST: 23.3 M (post-BNCT) TTP: 12.0 M (post-BNCT) 2-year OS: 43% |
[59] | |
1998–2007 | nGBM 08 | BSH, 5 g/body in 1 h BPA, 250 mg/kg in 1 h (BNCT and XRT) |
MST: 27.1 M (post-BNCT) TTP: 11.9 M (post-BNCT) 2-year OS: 63% |
[60] | |
2007 | HNC 01 | BPA, 400 mg/kg in 2 h (2 h before BNCT) BPA, 100 mg/kg in 1 h (during BNCT) (After one month, they received the second BNCT session) |
6 M after first BNCT, the tumor shrank significantly OS: NA |
[61] | |
Tokushima University, Japan | 1998–2000 | nGBM 06 | BSH, 100 mg/kg (12–15 h before BNCT) (IO-BNCT) |
MST: 15.3 M (post-diagnosis) 2-year OS: 0% |
[62,63,64] |
2001–2004 | nGBM 11 | BSH, 100 mg/kg (12–15 h before BNCT) (IO-BNCT) |
MST: 19.5 M (post-diagnosis) 2-year OS: 27.3% 3-year OS: 27.3% |
[62,63,64] | |
2001–2004 | nGBM 06 | BSH, 100 mg/kg (12 h before BNCT) BPA, 250 mg/kg (1 h before BNCT) |
MST: 26.2 M (post-diagnosis) 2-year OS: 50.0% 3-year OS: 16.7% |
[62,63,64] | |
2002–2003 | nGBM 03 rGBM 07 |
BSH, 5 g/body in 1 h (12 h before BNCT) BPA, 250 mg/kg in 1 h (1 h before BNCT) |
MST: 14.5 M (post-BNCT) | [65] | |
KURR, Osaka Medical College, Japan |
2002–2007 | rGBM 19 | BSH, 100 mg/kg in 1 h (12 h before BNCT) BPA, 250 mg/kg in 1 h or 700 mg/kg in 6 h (6 h before BNCT) |
MST: 10.8 M (post-BNCT) | [66] |
2002–2004 | nGBM 10 | BSH, 100 mg/kg in 1 h (12 h before BNCT) BPA, 250 mg/kg in 1 h (6 h before BNCT) |
MST: 14.1 M (post-BNCT) | [20,67] | |
2003–2006 | nGBM 11 | BSH, 100 mg/kg in 1 h (12 h before BNCT) BPA, 250 mg/kg in 1 h (6 h before BNCT) (BNCT and XRT) |
MST: 23.5 M (post-BNCT) | [20,67] | |
2010–2013 | nGBM 32 | BSH, 5 g/body in 1 h (12 h before BNCT) BPA, 500 mg/kg in 3 h (2 h before BNCT) (BNCT, XRT and TMZ) |
MST: 21.1 M (post-BNCT) (2-year OS: 45.5%) |
[68] | |
2005–2011 | rMM19 | BSH, 0 or 2.5 or 5.0 g/body in 1 h (12 h before BNCT) BPA, 400 mg/kg in 2 h (2 h before BNCT) BPA, 100 mg/kg in 1 h (during BNCT) |
MST: 14.1 M (post-BNCT) MST: 45.7 M (post-diagnosis) |
[69] | |
2013–2018 | rGBM 10 | BPA, 400 mg/kg in 2 h (2 h before BNCT) BPA, 100 mg/kg in 1 h (during BNCT) (BNCT and Bevacizumab) |
MST: 12 M (post-BNCT) TTP: 5.4 M (post-BNCT) |
[68,70] | |
2016–2018 | rGBM 24 | SPM-011, 400 mg/kg in 2 h (2 h before BNCT) SPM-011, 100 mg/kg in 1 h (during BNCT) |
MST: 18.9 M (post-BNCT) 1-year OS: 79.2% |
[71] | |
High Flux Reactor, Netherlands |
1997–2002 | nGBM 26 | BSA, 100 mg/kg in 1.7 h | MST: 10.4–13.2 M | [68,72] |
FiR-1 or Triga Mark II Reactor, Finland |
1999–2001 | nGBM 18 | BPA, 290~400 mg/kg in 2 h (irradiation started 45 min after injection) |
6 MOS: 100% (post-BNCT) 1-year OS: 61% (post-BNCT) |
[73] |
1999–2001 | rGBM 03 | BPA, 290 mg/kg in 2 h (irradiation started 45 min after injection) |
OS: 5 M, 7 M, >12 M (post-BNCT) |
[73] | |
2001–2008 | rGBM 20 AA 02 |
BPA, 290~450 mg/kg in 2 h (2 h before BNCT) | MST: 7 M (post-BNCT) TTP: 3 M (post-BNCT) 1-year OS: 36% |
[74] | |
2003–2012 | rHNC 79 | BPA, 350~400 mg/kg in 2 h (2 h before BNCT) (39 patients received a second BNCT session) |
MST: 10 M (post-BNCT) 2-year OS: 21% |
[75,76,77] | |
Nyköping hospital, Sweden, R2-0 reactor |
2001–2002 | nGBM 17 | BPA, 900 mg/kg in 6 h (8–9 h before BNCT) | MST: 12.4 M (post-BNCT) | [78] |
2001–2003 | nGBM 29 | BPA, 900 mg/kg in 6 h (8 h before BNCT) (13 patients received BNCT and TMZ) |
TTP (total): 5.8 M (post-BNCT) MST (total): 14.2 M (post-BNCT) MST (B): 11.6 M (post-BNCT) MST (B + T): 17.7 M (post-BNCT) |
[79,80] | |
2001–2005 | rGBM 12 | BPA, 900 mg/kg in 6 h (8 h before BNCT) | MST: 8.7 M (post-BNCT) MST: 22.2 M (post-diagnosis) TTP: 6 M (post-BNCT, 11 cases) |
[81] | |
2003–2004 | Case1: rMM Case2: rSC |
BPA, 900 mg/kg in 6 h (8 h before BNCT) | Case 1, PFS: 22 M (post-BNCT) OS: 32 M (post-BNCT) Case 2, PFS: 6 M (post-BNCT) OS: >26 M (post-BNCT) |
[82] | |
LVR-15 Reactor, Czech Republic |
2000–2002 | nGBM 05 | BSH, 100 mg/kg in 1 h | TTP: 2.5–6 M (4 cases) (One patient died of pulmonary embolism in the first week after irradiation) |
[83] |
BMRR, U.S. | 1994–1999 | nGBM 53 | BPA, 250~330 mg/kg in 2 h (irradiation started 45 min after injection) |
TTP: 18–34.5 W (post-diagnosis) MST: 12.8 M (post-diagnosis) 2-year OS: 9.4% |
[84] |
Harvard and MIT, U.S. |
1996–1999 | nGBM 20 | BPA, 250–350 mg/kg in 1~1.5 h (irradiation started 45 min after injection) |
MST: 11.1 M | [3,85,86] |
2002–2003 | nGBM 06 | BPA, 14 g/m2 in 1.5 h (irradiation started 45 min after injection) |
NA | [87] | |
THOR, National Tsing Hua University, Taiwan, China |
2010–2013 | rHNC 17 | BPA, 360 mg/kg in 2 h (2 h before BNCT) BPA, 45 mg/kg in 30 min (during BNCT) (15 patients received a second BNCT session) |
2-year local area control rate: 28% 2-year OS: 47% |
[88] |
2014–2018 | rHNC 07 | BPA, 360 mg/kg in 2 h (2 h before BNCT) BPA, 45 mg/kg in 30 min (during BNCT) (BNCT and IG-IMRT) |
1-year OS: 56% | [88] | |
KURR, Japan |
1987–2001 | MM 22 | BPA, 170–200 mg/kg in 3~5 h | CR: 73% (16/22) PR: 23% (5/22) |
[89] |
2012 | EMPD 02 | NA | PFS: >12 M | [90] | |
2005–2014 | MM 01 EMPD 03 |
BPA, 160 mg/kg in 2 h (2 h before BNCT) BPA, 40 mg/kg in 1 h (during BNCT) |
OS (Melanoma): 1.1 years OS (EMPD, 2 cases): >6 years (One EMPD patient died of heart disease after 3.2 years) |
[91] | |
RA-6, Argentina |
2003–2007 | MM 07 | BPA, 14 g/m2 in 1.5 h (1 patient received a second BNCT session) |
ORR: 69.3% CR: 9–100% |
[92] |
HNC, head and neck cancer; GBM, glioblastoma; AA, Anaplastic Astroglioma; MM, meningioma; SC, Stromal Chondrosarcoma; EMPD, extramammary Paget’s disease; IO-BNCT, intraoperative BNCT; n, newly diagnosed; r, recurrent; NA, not available; TMZ, temozolomide; XRT, X-ray treatment; n-year OS, n-year overall survival rate.